DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Natalie Grover - 2 Eva Mathews - 2 drugmaker - 1 James Goetz - 1 Emily Field - 1 Lucy Coutts - 1 JM Finn - 1 Goetz - 1
Top related locs:
U.S British London Bengaluru California Delaware Europe
Top related orgs:
GSK - 2 Pfizer - 2 Thomson - 2 Barclays - 1 GlaxoSmithKline - 1 REUTERS - 1 Sanofi - 1 Companies - 1

Search resuls for: "Natalie Grover Eva Mathews"


2 mentions found


☆ GSK soothes investors by settling first Zantac cancer lawsuit due for US trial
  + stars: | 2023-06-23 | by ( Natalie Grover Eva Mathews | Natalie Grover | Eva Mathews | ) www.reuters.com   time to read: +4 min
GSK on Friday said the settlement reflected its desire to avoid distraction related to protracted litigation in this case. It did not admit any liability and said it would vigorously defend itself in any other Zantac cases. The trial was due to start on July 24, the first test of how Zantac cancer claims would fare before a jury. Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares, said the Goetz settlement could create a precedent to settle other cases. "It also removes the distraction of any protracted litigation as the company must focus on its future pipeline which is where value will be created for shareholders," she said.
Persons: drugmaker, James Goetz, Emily Field, Lucy Coutts, JM Finn, Goetz, Dado Ruvic, Boehringer Ingelheim, Zantac, Natalie Grover, Eva Mathews, Dhanya Ann Thoppil, Barbara Lewis Organizations: GSK, Barclays, GlaxoSmithKline, REUTERS, Pfizer, Sanofi, Companies, Bank of America, FDA, Thomson Locations: U.S, British, California, Delaware, London, Bengaluru
☆ EU approves its first vaccine for common respiratory virus RSV
  + stars: | 2023-06-07 | by ( Natalie Grover Eva Mathews | Natalie Grover | Eva Mathews | ) www.reuters.com   time to read: +2 min
June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually. The shot, called Arexvy, is made by British drugmaker GSK (GSK.L) and is designed to protect people aged 60 and over. The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956. Given the different definitions of the trial endpoints across the GSK and Pfizer trials, a direct comparison of efficacy is difficult. In Europe, RSV leads to over 270,000 hospitalisations and about 20,000 in-hospital deaths in adults over 60 each year.
Persons: Luke Miels, Peter Welford, TD Cowen, Steve Scala, Natalie Grover, Eva Mathews, Maggie Fick, Savio D'Souza, Mark Potter Organizations: GSK, European Commission, European Medicines Agency, Reuters, U.S . Food, Drug Administration, Pfizer, Jefferies, Thomson Locations: British, Europe, U.S, London, Bengaluru
0 next >>
Total: 2